Top Markets
#1 MowCat MowCat +369.16%
#2 龙虾 (Lobster) 龙虾 (Lobster) +71.75%
#3 SODAX SODAX +51.21%
#4 Cortex Cortex +32.45%
#5 DexNet DexNet +23.19%
#6 MANTRA MANTRA +19.91%
#7 BNB Attestation Service BNB Attestation Service +17.96%
#8 Magma Finance Magma Finance +17.83%
#9 Akedo Akedo +16.88%
#10 wojak wojak +15.97%
Coin of the day
MowCat MowCat
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
D&D Pharmatech D&D Pharmatech

D&D Pharmatech

347850
Classificação em ações #7189
Established in 2014 and headquartered in Seongnam-si, South Korea, D&D... Established in 2014 and headquartered in Seongnam-si, South Korea, D&D Pharmatech Inc. is a clinical-stage biotechnology firm dedicated to discovering and advancing pharmaceutical treatments in both South Korea and the United States. The company's robust drug pipeline includes several candidates currently in clinical development: Phase II Trials: NLY01-PD, NLY01-AD, and NLY01-D are being investigated for their efficacy against Parkinson's disease, Alzheimer's disease, and type 2 diabetes, respectively. Completed Phase IIa Trial: P4M01 has successfully finished its Phase IIa study for the treatment of periodontal disease. Phase I Trials: A significant portion of its portfolio is in early human trials, encompassing DD01 for obesity, diabetes, and nonalcoholic steatohepatitis (NASH); TLY012, targeting NASH-liver fibrosis, chronic pancreatitis, and systemic sclerosis; PMI03, focused on Parkinson's disease, Alzheimer's disease, and neuroinflammation; PMI04, addressing Parkinson's disease, Alzheimer's disease, ALS, and depression; and PMI05 and PMI06, both exploring applications in oncology and immuno-oncology. Beyond the clinical stage, D&D Pharmatech is actively developing a range of preclinical compounds. These include NLY03 for stroke and Parkinson's disease; DD03 for obesity and NASH; TLY014, designed to modulate the tumor microenvironment; PMI31 for various cancer types; and VT01 for Parkinson's disease. Further research involves NLY02 for Parkinson's and Alzheimer's diseases; NLY12 for type 2 diabetes and obesity; DD02 for type 2 diabetes; PMI21 for prostate cancer; and PMI07 for oncology and fibrotic conditions. Additionally, the company strategically applies big data analytics to enhance its central nervous system drug research and diagnostics initiatives.
Preço da ação
$38.45
Valor de mercado
$1.68B
Variação (1 dia)
-1.24%
Variação (1 ano)
50.36%
País
KR
Negociar D&D Pharmatech (347850)

Categoria

Healthcare
Rácio P/E de D&D Pharmatech (347850)
Rácio P/E em 2026 TTM: 0
De acordo com os últimos relatórios financeiros e o preço das ações da D&D Pharmatech, o rácio P/E atual (TTM) é 0. No final de 2026, a empresa tinha um P/E de 0.
Histórico do rácio P/E da D&D Pharmatech de 2026 a 2026
Rácio P/E no final de cada ano
Ano Índice P/E Alterar
Não há dados suficientes para as datas fornecidas.
Rácio P/E para empresas semelhantes ou concorrentes
Empresa Rácio P/E Diferença do rácio P/E País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Como interpretar um P/E Ratio?

O rácio Preço/Lucro (P/E) mede a relação entre o preço da ação de uma empresa e o lucro por ação.
Um P/E baixo mas positivo representa uma empresa com altos lucros face à sua valorização atual e pode estar subvalorizada. Um P/E negativo elevado (perto de 0) representa perdas significativas.

Empresas com P/E acima de 30 ou negativo são geralmente vistas como "ações de crescimento", significando que os investidores esperam crescimento ou rentabilidade futura.

Empresas com P/E positivo inferior a 10 são geralmente consideradas "ações de valor", ou seja, já são muito lucrativas mas com pouco potencial de crescimento.